Blood loss is the leading cause of death in trauma patients between the ages of 1 and 46 years, largely because they cannot access safe blood sources quickly enough. A possible solution? Freeze-dried synthetic blood.
A multi-institutional team led by Dipanjan Pan, an Indian American professor, recently received a four-year, $2.7 million grant from the National Institutes of Health’s National Heart, Lung, and Blood Institute to develop the next generation of synthetic blood.
“Mother nature is hard to mimic, but we’re getting closer,” said Pan, a Dorothy Foehr Huck & J. Lloyd Huck Chair Professor in Nanomedicine and Professor in the Department of Nuclear Engineering and Materials Science and Engineering at Pennsylvania State University.
READ: Trump administration cancels over $12 billion in healthcare grants (March 27, 2025)
“Our goal is to design and optimize a blood substitute prototype, called Nano-RBC, that is based on a deformable nanoparticle. It is similar in shape to red blood cells and incorporates high-per-particle payloads of hemoglobin, the protein in red blood cells responsible for carrying oxygen.”
He explained that the odds of survival increase dramatically when a person can receive a transfusion before losing too much blood, but that’s often not possible in rural or war-torn areas without the specialized processing and storage facilities donated blood requires, according to a university release
“There is a need for an artificial oxygen carrier to substitute for banked blood in settings where stored blood is unavailable or undesirable,” Pan said. “Artificial blood is described as the ‘Holy Grail’ of trauma medicine. Researchers have been battling to develop it for 150 years, with many failures along the way.”
More recent efforts included agents that could not release oxygen in damaged tissue or overloaded the body with hemoglobin, which can raise iron in animals, including humans, to toxic levels when not managed.
“We are taking inspiration from these earlier failures and developing a next-generation functional system that attempts to mimic red blood cell physiological functions,” Pan said.
Pan and his team previously developed ErythroMer, an artificial blood product that emulates the physiological properties of red blood cells, like their ability to bind and release oxygen.
That work, conducted over a decade and currently in advanced stages of animal studies, was funded by more than $14 million in grants from the NIH, the Department of Defense and other agencies.
“While Erythromer emulated the functional and physiological properties of the red blood cells, our current project is taking this research forward to the next level by mimicking the morphological characteristics of red blood cells — their physical shape and how they move,” Pan said.
READ: DOGE leaders Elon Musk, Vivek Ramaswamy target 94% of remote federal workers (December 9, 2024)
The advanced version of the blood substitute product would have the same donut curve and thin, flat center of biological red blood cells, but would be one-tenth of the size. With the newly funded project, the researchers aim to further develop new materials that act and look like red blood cells and test their functionality in animal models.
“The ultimate goal is to develop safe, dried oxygen therapeutics envisioned for use when stored red blood cells are unavailable, undesirable or in short supply,” Pan said. “The inventiveness of materials researchers in health and medicine is limitless, and we’re demonstrating that in this ambitious and highly collaborative project.”